ImmunoGen Inc.(IMGN) recently provided an update on its pipeline and maintained its outlook for fiscal year 2013 (ending June 30) at its recently held Analyst & Investor Day.
Over a year ago, I told you about two companies pioneering a new therapeutic platform that provides the benefits of chemotherapy while reducing the side effects. Many of you are familiar with the...(read more
Last week, I mentioned how the Institute of Cancer Research recently discovered the driving force behind cancer’s ability to spread. And a drug that would potentially stop...(read more